Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin

Psychiatry and Clinical Neurosciences

Volumn 50, Issue 6, 1996, Pages 337-339

  Tokinaga, Noboru ^a   Kondo, Tsuyoshi ^a   Kaneko, Sunao ^a   Otani, Koichi ^a   Mihara, Kazuo ^a   Morita, Shigeru ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b Hirosaki Ohyokyo Kidney Res Ctr H   (Japan)

Author keywords

Benzodiazepine hypnotics; Erythromycin; Hallucinations

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CEFUZONAM; CILASTATIN PLUS IMIPENEM; ERYTHROMYCIN; HALOPERIDOL; NITRAZEPAM; STREPTOMYCIN; TRIAZOLAM;

ADULT; ANTIBIOTIC THERAPY; ANXIETY; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DEPRESSION; HUMAN; INSOMNIA; LOBAR PNEUMONIA; MALE; TREMOR; VISUAL HALLUCINATION;

ANTI-ANXIETY AGENTS; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; HALLUCINATIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRAZEPAM; PNEUMONIA; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRIAZOLAM;

EID: 0030451786     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1996.tb00577.x     Document Type: Article

References (12)

1. Rail TW. Hypnotics and sedatives; ethanol. In: Goodman Gilman A, Rail TW, Nies AS, Taylor P (eds.), The Pharmacological Basis of Therapeutics, 8th edn. Pergamon Press, New York, 1990; 345-382.
2. Van der Kroef C. Het Halcion-syndroom -een iatrogene epdiemie in Nederland. T. Ale. Drugs. 1982; 8: 156-162 (in Dutch).
3. Adam K, Oswald I. Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiatry 1989; 22: 115-119.
4. Bixler, EO, Kales-A, Manfredi RL, Vgontzas AN, Tyson KL, Kales JD. Next-day memory impairment with triazolam used. Lancet 1991; 337: 827-831.
5. Owen R, Tyrer P. Benzodiazepine dependence: a review of the evidence. Drugs 1983; 51: 385-398.
6. Sasa H, Otani K, Rondo T, Kaneko S, Fukushima Y. Alprazolam withdrawal symptoms. Br. J. Psychiatry 1990; 157: 154-155.
7. Mihara K., Kondo T, Otani K, Kaneko S, Fukushima Y. Does the co-administration of antidepressants facilitate the development of benzodiazepine withdrawal psychosis? J. Drug Dev, 1993; 5: 267-269.
8. Kroboth PD, Smith RB, Silver MR et al. Effects of end stage renal disease and aluminium hydroxide on triazolam, Pharmacokinetics. Br.J. Clin. Pharmacol. 1985; 19: 839-842.
9. Phillips JP, Antal EJ, Smith RB. A pharmacokineric drug interaction between erythromycin and triazolam. J. Clin. Psychopharmacol. 1986; 6: 297-299.
10. Kronbach T, Mathys D, Umeno M, Gonzales PJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450 3A4. Mol. Pharmacol. 1989; 36: 89-96.
11. Larry D, Funck-Brentano C, Brell P et al. Effects of erythromycin on hepatic drug-metabolizing enzyme in humans. Biochem. Pharmacol. 1983; 32: 1063-1068.
12. Warot D, Bergougnan L, Lamiable D et al. Troleandomycintriazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur. J. Clin. Pharmacol. 1987; 32: 389-393.